CTOs on the Move

Inflammatix

www.inflammatix.com

 
Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Joao Fonseca
 Chief Technology Officer Profile

Funding

Inflammatix raised $32M on 01/10/2020
Inflammatix raised $102M on 03/16/2021

Similar Companies

Inari

Inari embraces diversity in every aspect of our business to drive innovation and help build a new food system. Our technology matches the complexity of nature to transform seed using predictive design and multiplex gene editing – unlocking the full potential through our SEEDesign™ platform. The result is step-change products that lead to more productive acres and a more sustainable future for the food system.

Sequenom

Sequenom is a leading high-performance DNA analysis company organized into two distinct business units:Sequenom Genetic Systems and Sequenom Pharmaceuticals.

Ohana Biosciences

Ohana is pioneering a new frontier in reproductive medicine. Built upon a world-leading understanding of sperm biology, Ohana has created a best-in-class proprietary platform with broad applications across reproductive medicine.

Thrasos Therapeutics

Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease

Synosia Therapeutics

Synosia Therapeutics is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.